137 related articles for article (PubMed ID: 31646399)
1. Dexamethasone Degradation in Aqueous Medium and Implications for Correction of In Vitro Release from Sustained Release Delivery Systems.
Matter B; Ghaffari A; Bourne D; Wang Y; Choi S; Kompella UB
AAPS PharmSciTech; 2019 Oct; 20(8):320. PubMed ID: 31646399
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
[No Abstract] [Full Text] [Related]
3. Co-effect of aqueous solubility of drugs and glycolide monomer on in vitro release rates from poly(D,L-lactide-co-glycolide) discs and polymer degradation.
Kim JM; Seo KS; Jeong YK; Hai BL; Kim YS; Khang G
J Biomater Sci Polym Ed; 2005; 16(8):991-1007. PubMed ID: 16128233
[TBL] [Abstract][Full Text] [Related]
4. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A
Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233
[TBL] [Abstract][Full Text] [Related]
5. Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery.
Thalhauser S; Peterhoff D; Wagner R; Breunig M
Eur J Pharm Biopharm; 2020 Nov; 156():1-10. PubMed ID: 32860903
[TBL] [Abstract][Full Text] [Related]
6. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.
Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J
J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629
[TBL] [Abstract][Full Text] [Related]
7. Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants.
Costello MA; Liu J; Kuehster L; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
Mol Pharm; 2023 Dec; 20(12):6330-6344. PubMed ID: 37955890
[TBL] [Abstract][Full Text] [Related]
8. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
9. [Intravitreally injectable poly (D, L-Lactide) microspheres containing dexamethasone acetate for sustained release].
Wu W; Yang X; Lu B
Yao Xue Xue Bao; 2001 Oct; 36(10):766-70. PubMed ID: 12579978
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices.
Hickey T; Kreutzer D; Burgess DJ; Moussy F
Biomaterials; 2002 Apr; 23(7):1649-56. PubMed ID: 11922468
[TBL] [Abstract][Full Text] [Related]
11. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery.
Battiston K; Parrag I; Statham M; Louka D; Fischer H; Mackey G; Daley A; Gu F; Baldwin E; Yang B; Muirhead B; Hicks EA; Sheardown H; Kalachev L; Crean C; Edelman J; Santerre JP; Naimark W
Nat Commun; 2021 May; 12(1):2875. PubMed ID: 34001908
[TBL] [Abstract][Full Text] [Related]
12. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
[TBL] [Abstract][Full Text] [Related]
13. Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration.
Rodríguez Villanueva J; Bravo-Osuna I; Herrero-Vanrell R; Molina Martínez IT; Guzmán Navarro M
Eur J Pharm Sci; 2016 Sep; 92():287-97. PubMed ID: 26987610
[TBL] [Abstract][Full Text] [Related]
14. Often neglected: PLGA/PLA swelling orchestrates drug release: HME implants.
Bode C; Kranz H; Fivez A; Siepmann F; Siepmann J
J Control Release; 2019 Jul; 306():97-107. PubMed ID: 31150749
[TBL] [Abstract][Full Text] [Related]
15. Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats.
Barbosa Saliba J; Vieira L; Fernandes-Cunha GM; Rodrigues Da Silva G; Ligório Fialho S; Silva-Cunha A; Bousquet E; Naud MC; Ayres E; Oréfice RL; Tekaya M; Kowalczuk L; Zhao M; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1671-9. PubMed ID: 27054520
[TBL] [Abstract][Full Text] [Related]
16. Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye.
Awwad S; Day RM; Khaw PT; Brocchini S; Fadda HM
Int J Pharm; 2017 Apr; 522(1-2):119-127. PubMed ID: 28232270
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing dexamethasone intravitreal implants: Process control and critical quality attributes.
Costello MA; Liu J; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
Int J Pharm; 2023 Nov; 647():123515. PubMed ID: 37844672
[TBL] [Abstract][Full Text] [Related]
18. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(D,L-lactide-co-glycolide) microspheres.
Jiang G; Woo BH; Kang F; Singh J; DeLuca PP
J Control Release; 2002 Feb; 79(1-3):137-45. PubMed ID: 11853925
[TBL] [Abstract][Full Text] [Related]
19. Sustained release of ascorbate-2-phosphate and dexamethasone from porous PLGA scaffolds for bone tissue engineering using mesenchymal stem cells.
Kim H; Kim HW; Suh H
Biomaterials; 2003 Nov; 24(25):4671-9. PubMed ID: 12951010
[TBL] [Abstract][Full Text] [Related]
20. In Situ Forming Depot as Sustained-Release Drug Delivery Systems.
Kanwar N; Sinha VR
Crit Rev Ther Drug Carrier Syst; 2019; 36(2):93-136. PubMed ID: 30806210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
